BTAI - BioXcel Therapeutics Inc Analyst Forecast Prices

BioXcel Therapeutics (BTAI) is implementing neural networks to discover new properties of legacy drugs, offering the unique sublingual medication IGALMI, although heavy revenue reliance on a single product creates financial risks. The stock's price history relative to the consensus forecast, where the value is 1.00, clearly demonstrates market expectations. Market capitalization is growing due to the supply of antipsychotic treatments to gerontology centers and psychiatric hospitals.

Analyst Consensus Forecast: BioXcel Therapeutics, Inc. (BTAI) for 07/04/2022 - 09/19/2026

Analytical breakdowns for BioXcel (BTAI)

- current price and projected stock value:

Price Chart bioxceltherapeutics.com|BTAI - Consensus Target

- market capitalization statistics:

Market Value BioXcel|BTAI - Enterprise Value

- book capitalization information:

Book Value per Share BioXcel Therapeutics|BTAI - Book Capitalization|Market Capitalization to Book Value bioxceltherapeutics.com|BTAI - Aggregate Company Assets

- debt obligations and liquidity statistics:

Aggregate Debt to Equity BioXcel Therapeutics|BTAI - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital BioXcel Therapeutics Corp|BTAI - Company Aggregate Debts|Debts to Book Capitalization BioXcel|BTAI - Company Long-Term Debt|Company Short-Term Loans and Borrowings BioXcel Therapeutics|Quick Liquidity Indicator bioxceltherapeutics.com

- company profitability and valuation multiples indicators:

BTAI - Net Profit|Projected Future Earnings BioXcel Therapeutics|BTAI - Price to Earnings Ratio|Future Price to Earnings Multiple BioXcel Therapeutics Inc|BTAI - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation BioXcel|BTAI - Operating profit EBITDA|Net earnings per one share for the last twelve months BioXcel Therapeutics|BTAI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth bioxceltherapeutics.com|BTAI - Earnings per share growth in current year|Expected earnings per share trend next year BioXcel Therapeutics

General company analysis:BTAI bioxceltherapeutics.com

Flagship merchandise of BioXcel Therapeutics Corp

BioXcel Therapeutics (BTAI) resilience to macroeconomic pressure depends on the monetization of AI patents and the protection of Igalmi rights, which requires significant legal expenses. The consensus price target trajectory reflects the weighted average analyst valuation, signaling a risk of capital impairment amid margin compression, which allows investors to distinguish an attractive discount from a systemic decline in business value.

Competitors of BioXcel Therapeutics